SonaCare Medical Announces Platinum Sponsorship of 7th International Symposium on Focal Therapy and Imaging in Prostate & Kidney Cancer

Ablative device manufacturer sponsors international focal therapy symposium, highlights HIFU sessions and invites international attendees to connect with key opinion leaders and company management.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
SonaCare Medical Logo

SonaCare Medical

The symposium is truly regarded as a great source of learning about state-of-the art technology and we are excited to be a part of it.

Charlotte, NC (PRWEB) August 15, 2014

SonaCare Medical, LLC, the global leader in urologic high intensity focused ultrasound (HIFU), is proud to provide platinum support for the upcoming 7th International Symposium on Focal Therapy and Imaging in Prostate & Kidney Cancer. This year’s symposium takes place at the Langham Huntington Resort in Pasadena, CA from August 21st to 23rd and includes faculty members from seven countries who have put together a comprehensive scientific program including multiple HIFU sessions.

As the leading international symposium on focal therapy, the event alternates annually between the United States and the Netherlands and is hosted by the University of Southern California this year. The three day scientific program contains several HIFU centered courses and presentations including: hands-on HIFU workshops for renal and prostate ablation, a HIFU guidance video session presented by Stephen Scionti, M.D., a presentation by Hash Ahmed, M.D. on focal therapy energy delivery methods, and a presentation on HIFU for small renal masses by Chandru Sundaram, M.D.

“We are especially excited about this year’s renal program as several top urologic centers at leading universities in the United States have recently acquired our Sonatherm® laparoscopic HIFU system, which is 510(k) cleared in the USA for soft tissue ablation” says SonaCare CEO Michael Klein. “This is the first year that the symposium has a hands-on kidney ablation workshop as well as a presentation on the use of HIFU for renal cancer. We are encouraged by the demand for Sonatherm in the USA and are on track for establishing a number of Luminary HIFU Centers nationwide this year.”

The symposium generally also attracts attendees from around the world. “Many European and South American SonaCare HIFU physicians are excited about the opportunity to connect with peers and observe best practices from around the world” noted Alex Gonzalez, Vice President of International Operations at SonaCare. “Our users are very interested in learning more about our new Sonatherm® laparoscopic probe. The symposium is truly regarded as a great source of learning about state-of-the art technology and we are excited to be a part of it.”

All intrigued physicians are encouraged to connect with existing users, management and researchers at SonaCare Medical’s booth in the International Symposium on Focal Therapy’s exhibition hall. Additional information can be found at http://www.sonacaremedical.com.

About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company, is a world leader in minimally-invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500, which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C.


Contact

Past News Releases Group Rss Subscribe